Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive RFA for Esophageal Speckled Lugol Background Mucosa
NCT03183115Recruiting
- Sponsor
- E-Da Hospital
- Start
- Apr 2016
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by E-Da Hospital. Primary endpoint: Tumor recurrence at 100 months. Started Apr 2016; status: recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03183115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03183115.